「sample-size」の検索結果

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Design and analyze A/B tests: sample size, test duration, and statistical significance for conversion experiments. Use when setting up an A/B test, calculating sample size, designing an experiment, or analyzing results.

日本語の概要は準備中です。原文の説明を表示しています。

Use when planning how many patients or cases a study needs before data collection (power analysis, IRB justification). Walks a decision tree to the right test and returns reproducible R/Python code and IRB-ready justification text. Analyzing collected data is /analyze-stats.

日本語の概要は準備中です。原文の説明を表示しています。

Use when data needs statistical analysis. Runs reproducible Python/R code for Table 1, diagnostic accuracy, agreement, regression, survival, propensity score, survey-weighted and repeated-measures models, with publication tables. Sample size is /calc-sample-size; pooling studies is /meta-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Guides privacy audit sampling methodology including statistical and non-statistical sampling, sample size determination, stratification techniques, attribute sampling for compliance testing, confidence level selection, tolerable deviation rates, and extrapolation of results to the population. Keywords: audit sampling, statistical sampling, attribute testing, sample size, confidence level, stratified sampling, privacy audit.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Plans a controlled experiment (A/B test) so its result can be trusted: writes the hypothesis, picks one primary metric and the guardrails, computes sample size and run time, specifies how visitors are assigned and when exposure is logged, and reads out the result with a confidence interval. Use when someone says "set up an A/B test", "split test this page", "how many visitors do I need", "how long should the experiment run", "is this result significant", "can I stop the test early", or wants to test a headline, price, layout or onboarding change against the current version.

日本語の概要は準備中です。原文の説明を表示しています。

Audits a methods section against a 45-item reporting checklist synthesized from the APSA Experimental Section rubric, JARS-Quant, CONSORT, and DA-RT, covering pre-registration, recruitment, randomization and treatments, sample flow and attrition, sample-size justification, three-tier results labeling, conjoint reporting, validity, and open-science infrastructure. Use when checking whether a methods section reports enough, preparing a submission or replication archive, asking what CONSORT, JARS, or DA-RT require, or documenting a deviation from a pre-analysis plan. Writing that plan before data collection goes to pre-registration-writing.

日本語の概要は準備中です。原文の説明を表示しています。

Design and evaluate paid-ad experiments with hypotheses, randomization units, sample-size and duration assumptions, guardrails, platform experiment tools, analysis, and decision rules. Use for A/B test, split test, experiment design, hypothesis, statistical significance, sample size, test duration, or experiment readout.

日本語の概要は準備中です。原文の説明を表示しています。

Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to "design an email A/B test", "set up a multivariate subject/CTA test", "run a send-time test", "build a hold-out group", or "is this email result statistically and practically material?"; produces a falsifiable hypothesis, one-variable-per-cell matrix, sample-size/MDE/duration/power plan, and an effect/uncertainty read from own ESP data. Applies only a precommitted owner-approved action rule; the helper never chooses a business action. Not for EQS/vetoes or writing the email. 邮件AB测试设计/多变量测试/发送时间测试/留出组/显著性判定

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to "design an A/B test", "set up a creative/landing test", "run an incrementality test", or "is this result statistically and practically material?"; produces a hypothesis, variant matrix, sample-size/duration/power plan, and a documented effect/uncertainty read from own exported results. It applies only a precommitted owner-approved action rule; the statistical helper never chooses a business action. Not for producing variants — use ad-creative-builder; not for reading back one shipped change — use paid-measurement-loop. 广告AB测试设计/实验设计/显著性判定/增效测试

日本語の概要は準備中です。原文の説明を表示しています。

Design and evaluate paid-ad experiments with hypotheses, randomization units, sample-size and duration assumptions, guardrails, platform experiment tools, analysis, and decision rules. Use for A/B test, split test, experiment design, hypothesis, statistical significance, sample size, test duration, or experiment readout.

日本語の概要は準備中です。原文の説明を表示しています。

A/B testing specialist v3 — hypothesis, sample size, statistical significance, Bayesian

日本語の概要は準備中です。原文の説明を表示しています。

Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Validates predictive models on omics and biomedical data with nested cross-validation, group/batch/temporal-aware splits, the full data-leakage taxonomy, probability calibration, decision-curve net benefit, optimism correction, sample-size planning, and TRIPOD+AI reporting. Use when estimating model performance honestly, choosing a CV scheme, detecting leakage, or judging whether reported discrimination means the model is actually useful. For feature selection itself see machine-learning/biomarker-discovery; for confirmatory-trial inference see clinical-biostatistics/trial-reporting.

日本語の概要は準備中です。原文の説明を表示しています。

Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。